![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Phase II, open-label trial in treatment-naïve, HIV-1-infected patients who received DRV/r as induction monotherapy
|
|
|
Reported by Jules Levin
EACS Nov 13 2009, Cologne, Germany
Patricia Patterson,1 Alejandro Krolewiecki,1 Frank Tomaka,2 Sabrina Spinosa-Guzman,3 Diego Miralles4 and Pedro Cahn1
1Fundacion Huesped, Buenos Aires, Argentina;
2Tibotec Inc, Yardley, PA, USA; 3Tibotec BVBA, Mechelen, Belgium; 4PRD West Coast Research Center, San Diego, CA, USA
![image002.gif](../images/111719/111719-5/image002.gif)
![image004.gif](../images/111719/111719-5/image004.gif)
![image006.gif](../images/111719/111719-5/image006.gif)
![image008.gif](../images/111719/111719-5/image008.gif)
1. Squires et al, 5th IAS 2009. Abstract TUAB106-LB; Ripamonti et al, 12th EACS 2009. Abstract PS4/1
![image010.gif](../images/111719/111719-5/image010.gif)
![image012.gif](../images/111719/111719-5/image012.gif)
*The following polymorphisms were allowed as they have no known effect on DRV susceptibility: I13V, K20I/M/R, M36I/V, D60E, I62V, L63P, A71T/V, V77I and I93L
![image014.gif](../images/111719/111719-5/image014.gif)
![image016.gif](../images/111719/111719-5/image016.gif)
![image018.gif](../images/111719/111719-5/image018.gif)
![image020.gif](../images/111719/111719-5/image020.gif)
![image022.gif](../images/111719/111719-5/image022.gif)
![image024.gif](../images/111719/111719-5/image024.gif)
![image026.gif](../images/111719/111719-5/image026.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|